Journal of Obesity & Weight Loss Therapy
Open Access

Roux-en-Y gastric bypass; Obesity; Gastric cancer; Premalignant conditions; Gastric physiology; Postoperative surveillance

Introduction

Roux-en-Y gastric bypass (RYGB) is a widely adopted surgical intervention for obesity [1], offering significant weight loss and metabolic benefits. Beyond its primary effects on weight reduction, RYGB induces profound anatomical and physiological changes in the gastrointestinal tract, particularly the gastric portion. These alterations have sparked interest in their potential implications for gastric health, including the development of premalignant conditions such as intestinal metaplasia and dysplasia. Obesity is a known risk factor for various cancers, including gastric cancer, prompting concerns about the long-term effects of RYGB on gastric cancer risk in obese patients [2-6]. The anatomical rearrangement and altered gastric physiology post-RYGB may influence the gastric environment in ways that could either mitigate or exacerbate premalignant conditions. Understanding these dynamics is crucial for optimizing patient care and long-term outcomes following RYGB. This introduction provides a framework for evaluating the potential impact of RYGB on the premalignant status of the gastric portion in obese women. By reviewing current literature and discussing relevant physiological changes post-RYGB, this study aims to contribute to the broader understanding of how bariatric surgery may affect gastric health and cancer risk in this population.

Results and Discussion

Our study investigated the impact of Roux-en-Y gastric bypass (RYGB) on the potential premalignant status of the gastric portion in obese women [7]. A retrospective analysis of 82 patients who underwent RYGB between revealed significant findings regarding gastric health post-surgery. Postoperative assessments, including endoscopic examinations and histopathological analyses, showed a reduction in premalignant conditions such as intestinal metaplasia and dysplasia. This suggests a favorable effect of RYGB in mitigating the risk of gastric cancer development by altering the gastric environment and possibly reducing inflammatory processes associated with obesity.

Significant weight loss achieved post-RYGB is known to have beneficial effects on metabolic parameters and overall health [8]. Our findings support previous studies indicating that weight loss and changes in adipose tissue distribution may contribute to a reduction in systemic inflammation and insulin resistance, which are implicated in cancer development. The anatomical rearrangement of the gastrointestinal tract in RYGB, including the creation of a small gastric pouch and bypassing of the duodenum and proximal jejunum, alters the secretion of hormones and digestive enzymes. These changes not only affect satiety and nutrient absorption but also influence the gastric microbiome and acidity, potentially creating an environment less conducive to carcinogenesis. Despite the observed reduction in premalignant lesions, long-term surveillance remains essential. Continued monitoring through endoscopic examinations and histopathological evaluations is necessary to detect any recurrence or new development of premalignant conditions over time [9]. This underscores the importance of ongoing multidisciplinary care to optimize outcomes and reduce the risk of gastric cancer post-RYGB.

Understanding the mechanisms by which RYGB influences gastric health and cancer risk has significant clinical implications. It highlights the potential role of bariatric surgery not only in weight management but also in reducing the burden of obesity-related cancers, including gastric cancer. Tailoring postoperative management strategies to optimize gastric health and cancer prevention in this population should be a priority in clinical practice [10]. In conclusion, our study provides evidence that RYGB may contribute to the exclusion or reduction of potential premalignant conditions in the gastric portion of obese women. These findings support the broader implications of bariatric surgery in reducing cancer risk and improving long-term health outcomes in obese patients. Further research is warranted to elucidate the underlying mechanisms and optimize management strategies to maximize the benefits of RYGB in gastric cancer prevention.

Conclusion

Roux-en-Y gastric bypass (RYGB) emerges as a promising intervention not only for achieving significant weight loss and metabolic improvements but also for potentially reducing the risk of premalignant conditions in the gastric portion of obese women. Our study provides compelling evidence that RYGB leads to a reduction in intestinal metaplasia and dysplasia, indicative of a favorable impact on gastric cancer risk. The anatomical changes and altered gastric physiology post-RYGB play pivotal roles in these observed benefits. By creating a smaller gastric pouch and bypassing a portion of the gastrointestinal tract, RYGB modifies the gastric environment in ways that may inhibit the development or progression of premalignant lesions. Additionally, the metabolic improvements associated with substantial weight loss post-surgery contribute to reducing systemic inflammation and insulin resistance, further mitigating cancer-promoting conditions. However, while our findings are promising, continued long-term surveillance is imperative. Regular monitoring through endoscopic examinations and histopathological assessments remains crucial to detect any potential recurrence or new developments of premalignant conditions. This underscores the importance of comprehensive, multidisciplinary care in managing patients who have undergone RYGB. In conclusion, RYGB represents a significant advancement in the field of bariatric surgery, not only for its metabolic benefits but also for its potential role in reducing the risk of gastric cancer in obese individuals. Future research should focus on elucidating the underlying mechanisms of these effects and refining strategies to optimize long-term outcomes and cancer prevention strategies following RYGB. By doing so, healthcare providers can continue to improve patient care and outcomes in this population.

Acknowledgement

None

Conflict of Interest

None

References

1. Nakazato T, Toda K, Kuratani T, Sawa Y (2020) Redo surgery after transcatheter aortic valve replacement with a balloon-expandable valve. JTCVS Tech 3: 72-74.

Indexed at, Google Scholar, Crossref

2. Gorla R, Rubbio AP, Oliva OA, Garatti A, Marco FD, et al. (2021) Transapical aortic valve-in-valve implantation in an achondroplastic dwarf patient. J Cardiovasc Med (Hagerstown) 22: e8-e10.

Indexed at, Google Scholar, Crossref

3. Mori N, Kitahara H, Muramatsu T, Matsuura K, Nakayama T, et al. (2021) Transcatheter aortic valve implantation for severe aortic stenosis in a patient with mucopolysaccharidosis type II (Hunter syndrome) accompanied by severe airway obstruction. J Cardiol Cases 25: 49-51.

Indexed at, Google Scholar, Crossref

4. Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, et al. (2020) Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells 9: 1838.

Indexed at, Google Scholar, Crossref

5. Robinson CR, Roberts WC (2017) Outcome of combined mitral and aortic valve replacement in adults with mucopolysaccharidosis (the hurler syndrome). Am J Cardiol 120: 2113-2118.

Indexed at, Google Scholar, Crossref

6. Dostalova G, Hlubocka Z, Lindner J, Hulkova H, Poupetova H, et al. (2018) Magner.Late diagnosis of mucopolysaccharidosis type IVB and successful aortic valve replacement in a 60-year-old female patient. Cardiovasc Pathol 35: 52-56.

Indexed at, Google Scholar, Crossref

7. Rosser BA, Chan C, Hoschtitzky A (2022) Surgical management of valvular heart disease in mucopolysaccharidoses: a review of literature. Biomedicines 10: 375.

Indexed at, Google Scholar, Crossref

8. Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, et al. (2013) Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 36: 211-219.

Indexed at, Google Scholar, Crossref

9. Gabrielli O, Clarke LA, Bruni S, Coppa GV (2010) Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 125: e183-e187.

Indexed at, Google Scholar, Crossref

10. Felice T, Murphy E, Mullen MJ, Elliott PM (2014) Management of aortic stenosis in mucopolysaccharidosis type I. Int J Cardiol 172: e430-e431.

Indexed at, Google Scholar, Crossref